Table 2 Randomised studies evaluating epidermal growth factor receptor inhibitors in advanced colorectal cancer

From: Treatment in advanced colorectal cancer: what, when and how?

Study

Treatment arms

Number of patients

Response rates (%)

P -value

Median progression-free survival (months)

P -value

Median overall survival (months)

P -value

First line

        

Van Cutsem et al (2009)

FOLFIRI

599

38.7

—

8.0

—

18.6

—

CRYSTAL

FOLFIRI + cetuximab

599

46.9

0.004

8.9

0.048

19.9

0.31

Bokemeyer et al (2009) a

FOLFOX

168

36

—

7.2

—

NR

NR

OPUS

FOLFOX + cetuximab

169

46

0.064

7.2

0.62

NR

 

Borner et al (2008) a

CAPOX

37

14

—

5.8

—

16.5

—

SAKK

CAPOX + cetuximab

37

41

NR

7.2

NR

20.5

NR

Heinemann et al (2008) a

CAPIRI +cetuximab

93

47

—

6.7

—

NR

—

German AIO

CAPOX + cetuximab

92

48

NR

7.9

NR

NR

NR

Ciuleanu et al (2008) a

FOLFIRI +cetuximab

78

45

—

8.3

—

18.9

—

CECOG

FOLFOX +cetuximab

77

43

NR

8.6

NS

17.4

NR

Hecht et al (2009)

FOLFOX + BEV

410

48

—

11.4

HR: 1.27

24.5

HR: 1.43

PACCE

FOLFOX + BEV + PAN

413

46

NS

10.0

(95% CI: 1.06–1.52)

19.4

(95% CI: 1.11–1.83)

Hecht et al (2009)

FOLFIRI + BEV

115

40

—

11.7

HR: 1.19

20.5

HR: 1.42

PACCE

FOLFIRI + BEV + PAN

115

43

NS

10.1

(95% CI: 0.79–1.79)

20.7

(95% CI: 0.77–2.62)

Second line

Sobrero et al (2008)

Irinotecan

650

4.2

<0.0001

2.6

<0.0001

9.99

0.7115

EPIC

Irinotecan + cetuximab

648

16.4

 

4.0

 

10.71

 

Third and subsequent line

Jonker et al (2007)

BSC

285

0

<0.001

1.8

<0.001

4.6

0.005

NCIC CO17

Cetuximab + BSC

287

8

 

1.9

 

6.1

 

Van Cutsem et al (2007)

BSC

232

0

<0.0001

1.8

<0.0001

NR

0.81

 

Panitumumab + BSC

231

10

 

2

 

NR

 

Cunningham et al (2004)

Cetuximab

111

10.8

0.0074

1.5

<0.001

6.9

0.48

BONDa

Irinotecan + cetuximab

218

22.9

 

4.1

 

4.8

 

Tejpar et al (2007) EVERESTa

Irinotecan + cetuximab (standard dose)

45

16

—

3.9

—

10

—

 

Irinotecan + cetuximab (escalating dose)

44

30

NR

4.8

NR

8.6

NR

Wilke et al (2008) MABELb

Irinotecan + cetuximab

1147

20.1

—

3.2

—

9.2

—

  1. LV=leucovorin; FOLFOX=oxaliplatin/infused 5-FU/LV; BEV=bevacizumab; FOLFIRI=irinotecan /infused 5-FU/LV; CAPOX=capecitabine/oxaliplatin; BSC=best supportive care; PAN=panitumumab; NR=not reported; HR=hazard ratio; CI=confidence interval.
  2. The first treatment arm of each study was the control study.
  3. All P-values were compared with control arms.
  4. aRandomised phase II studies.
  5. bObservational registry studies.
Back to article page